Brookwood Investment Group LLC Trims Holdings in Johnson & Johnson $JNJ

Brookwood Investment Group LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 49.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,899 shares of the company’s stock after selling 2,883 shares during the period. Brookwood Investment Group LLC’s holdings in Johnson & Johnson were worth $443,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. GFG Capital LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson during the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson during the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson during the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson during the 1st quarter worth approximately $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Barclays upped their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Stifel Nicolaus boosted their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Trading Down 0.0%

Shares of Johnson & Johnson stock opened at $190.31 on Tuesday. The company has a fifty day simple moving average of $182.54 and a 200-day simple moving average of $166.65. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a market cap of $458.50 billion, a price-to-earnings ratio of 18.37, a PEG ratio of 2.24 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.